AI Article Synopsis
- The review evaluated existing data on the effectiveness of glucosamine and chondroitin for treating osteoarthritis, focusing on high-quality studies.
- It included seven meta-analyses, one systematic review, and five randomized clinical trials, all meeting strict inclusion criteria.
- Findings suggest that glucosamine and chondroitin offer no significant clinical benefits for knee or hip osteoarthritis, indicating a need for further research.
Article Abstract
To evaluate the current evidence that support or disprove the use of glucosamine and chondroitin in the treatment of patients with osteoarthritis. We performed a literature review using the databases of Medline, PubMed and the Cochrane Controlled Trial Register and Cochrane Databases Systematic Reviews (Cochrane Library). We considered only studies with high level of evidence. The study included analysis of randomized controlled trials that included at least 100 patients in each intervention group, meta-analyzes and systematic reviews. Seven meta-analysis, one systematic review and five randomized clinical trials fit inclusion criteria of this review. Considering the best evidences until now, the use of glucosamine and chondroitin does not provide clinical relevant benefits to patients with osteoarthritis of the knee or hip (Level I of evidence and grade A of recommendation). Further trials with adequate technology are necessaries to elucidate this question.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6565901 | PMC |
| http://dx.doi.org/10.1016/j.rboe.2012.12.001 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Therapeutic reduction of neurocan in murine intracerebral hemorrhage lesions promotes oligodendrogenesis and functional recovery.
J Neuroinflammation
January 2025
Department of Cerebrovascular Diseases, The Second Affiliated Hospital of Zhengzhou University, 2 Jingba Road, Zhengzhou, Henan, China.
Background: Intracerebral hemorrhage (ICH) causes prominent deposition of extracellular matrix molecules, particularly the chondroitin sulphate proteoglycan (CSPG) member neurocan. In tissue culture, neurocan impedes the properties of oligodendrocytes. Whether therapeutic reduction of neurocan promotes oligodendrogenesis and functional recovery in ICH is unknown.
View Article and Find Full Text PDF[Chondroprotective therapy and adjuvant support for patients with chronic lower back pain].
Zh Nevrol Psikhiatr Im S S Korsakova
December 2024
International University of Restorative Medicine, Moscow, Russia.
The trend of an annual increase in the detection of new cases of osteoarthritis (OA) and an increase in the number of patients with chronic lower back pain (LBP) calls for the search for new drugs and pharmaconutraceuticals with anti-inflammatory and chondroprotective properties. In 2019, approaches to the treatment of pain in OA significantly changed. In international and Russian clinical guidelines (CG), pharmaconutraceutical chondroitin sulfate (CS) and glucosamine sulfate (GS) are recommended for OA of different localization as a basic therapy.
View Article and Find Full Text PDFComparative Efficacy of Glucosamine-Based Combination Therapies in Alleviating Knee Osteoarthritis Pain: A Systematic Review and Network Meta-Analysis.
J Clin Med
December 2024
Department of Physical Therapy, College of Healthcare Medical Science & Engineering, Gimhae 50834, Republic of Korea.
The lack of definitive scientific evidence sustains uncertainty about the efficacy of glucosamine and its combination therapies for knee osteoarthritis (KOA), contributing to an ongoing debate among clinical practice guidelines and healthcare practitioners. This systematic review and network meta-analysis (NMA) aimed to identify the most effective glucosamine combination therapy for KOA patients. Frequentist random-effects models were employed for this NMA, with standardized mean differences (SMDs) and 95% confidence intervals (CIs) calculated for primary outcomes.
View Article and Find Full Text PDFNovel formulations ameliorate osteoarthritis in rats by inhibiting inflammation and oxidative stress.
Food Sci Nutr
October 2024
Department of Animal Nutrition, Faculty of Veterinary Medicine Firat University Elazig Turkey.
The study tested new oral plant-based formulations (F) on rats with monosodium iodoacetate (MIA)-induced osteoarthritis, measuring inflammation, antioxidant levels, paw size, stride, and analyzing knee joint images. Fifty-six female Sprague Dawley rats were allocated into 8 groups: (1) Control, (2) MIA (OA induced with MIA), (3) MIA + F1 [curcuminoids+gingerols+acetyl-11-keto-β boswellic acid (AKBA)], (4) MIA + F2 (curcuminoids+Withania glycosides+AKBA), (5) MIA + F3 (curcuminoids+total withanolides+AKBA), (6) MIA + F4 (curcuminoids, AKBA), (7) MIA + UCII (type II collagen), and (8) MIA + GCHON (Glucosamine Chondroitin). Treatments F1 to F4 reduced right joint diameter and improved stride length and paw area in OA rats.
View Article and Find Full Text PDFReview perspective on advanced nutrachemicals and anterior cruciate ligament rehabilitation.
Z Naturforsch C J Biosci
October 2024
Faculty of Applied Science, 283706 Lincoln University College, Petaling Jaya, Selangor Darul Ehsan 47301, Malaysia.
Anterior cruciate ligament (ACL) injuries are prevalent among athletes, necessitating surgical intervention followed by comprehensive rehabilitation. Recently, the integration of nutraceuticals - bioactive compounds from food sources - into rehabilitation protocols has shown promise in enhancing recovery outcomes. This review explores the potential benefits of various nutraceuticals, including omega-3 fatty acids, collagen supplements, vitamin D, glucosamine and chondroitin, curcumin, and branched-chain amino acids (BCAAs), in ACL rehabilitation.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!